TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04493853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abiraterone Acetate
Description: Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.
Study: NCT03695601

Intervention type: OTHER
Intervention: Standard of Care
Description: Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
Study: NCT03867175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
Study: NCT03146741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zepatier
Description: Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
Study: NCT01421641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracervical Lidocaine Injection
Description: Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Lidocaine Gel
Description: Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
Study: NCT01881607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESPIRNET Program
Description: The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program.
Study: NCT03269903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILZO esophageal stent
Description: A fully covered esophageal self-expandable metal stent for malignant dysphagia
Study: NCT01360346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enteral Sedation (EN)
Description: Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
Study: NCT01360346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Intravenous Sedation (IV)
Description: Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
Study: NCT03162406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral supplementation 25000 IU once per week for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplementation once per week for 6 months
Study: NCT03093441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal High-Intensity Interval Training Intervention
Description: The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal High-Intensity Interval Training Intervention
Description: The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
Study: NCT01889368

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape Seed Extract
Description: 300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
Study: NCT00661635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
Study: NCT04001192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise program
Description: The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
Study: NCT01095627

Intervention type: OTHER
Group type: OTHER
Intervention: Metacholine challenge
Description: Exhaled breath analysis following metacholine challenge
Study: NCT00837967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler
Description: 160/4.5μg for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbuhaler
Description: 160/4.5μg for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline Turbuhaler
Description: 0.4 mg for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline Turbuhaler
Description: 0.4 mg for 3 days
Study: NCT02356952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean Diet
Description: A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
Study: NCT02908152

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: 1500 mg~1 capsule / day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1500 mg~1 capsule / day for 12 weeks
Study: NCT02308449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride (placebo)
Description: Infusion of 250 mL 0.9% sodium chloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride (placebo)
Description: Infusion of 250 mL 0.9% sodium chloride
Study: NCT04211012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Nab-Paclitaxel +/- cisplatin
Description: Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin
Study: NCT02602314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT04494295

Intervention type: DEVICE
Intervention: Aurora Surgiscope System
Description: MIS evacuation of hematoma using the Aurora Surgiscope System
Study: NCT02412176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacing site - the implantation in the right ventricular (RV) apex
Description: Pacing site - RV apex. The lead will be implanted in the RV apex.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pacing site - the implantation in the septum
Description: Pacing site - septum. The lead will be implanted in the septum.
Study: NCT03307941

Intervention type: DRUG
Group type: OTHER
Intervention: Monalizumab
Description: Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level

Intervention type: DRUG
Group type: OTHER
Intervention: 5-Fluorouracil
Description: A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level

Intervention type: RADIATION
Group type: OTHER
Intervention: Metabolic
Description: Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Metabolic
Description: 18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
Study: NCT02583022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 cream 1.0%
Description: Topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 cream vehicle
Description: Topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel cream 1%
Description: Topical application
Study: NCT04579003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization posterolateral glide for 30 secs with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilization with movement
Description: Moist hot pack for 10 mins/1 set/ 6 consecutive days, Ultrasound for 5 mins/1 set/ 6 consecutive days, TENS on shoulder region for 10 mins/1 set/ 6 consecutive days, Shoulder mobilization with movement (MWM) 10 repetitions with 30 secs rest for 5 mins.~A total of 6 consecutive sessions were given each consisting of 30 mins.
Study: NCT02374424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA101_DHAP
Description: Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~* GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~* Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~* Dexamethasone 40 mg day 1-4 of every cycles~* Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~* GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy
Study: NCT01166750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CD-ROM
Description: Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control Group
Description: Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
Study: NCT03649893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Office
Description: Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
Study: NCT02235025

Intervention type: OTHER
Group type: OTHER
Intervention: Cardio-pulmonary exercise testing

Intervention type: OTHER
Group type: OTHER
Intervention: Cardio-pulmonary exercise testing

Intervention type: OTHER
Group type: OTHER
Intervention: Cardio-pulmonary exercise testing
Study: NCT00532532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolperisone HCl
Description: Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study: NCT03958474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Participants receive oxycodone or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Participants receive oxycodone or placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
Study: NCT00532532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolperisone HCl
Description: High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolperisone HCl
Description: Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study: NCT02420262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Injected s.c./subcutaneously (under the skin) before each main meal.
Study: NCT05455151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative therapy
Description: Conservative therapy to which the patients were subjected was the effect of an electrical impulse

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: This intervention consisted of injecting platelet-rich plasma (PRP) into the endometrium

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of PRP after conservative therapy
Description: This intervention consisted of conducting conservative therapy with an electrical impulse and then injecting PRP inside the endometrium

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of PRP with endometrial cells
Description: This intervention consisted of injecting endometrial cells suspended in prp
Study: NCT03404388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: 4 days of a challenging balance training task
Study: NCT03210051

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
Study: NCT04360369

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOP with Goldmann Applanation Tonometer
Description: Measurement of intraocular pressure (IOP) with Goldmann Applanation Tonometer. Measurement will be used to categorize each subject as having Low IOP (7 to 16 mmHg), Medium IOP (\>16 to \<23 mmHg), or High IOP (\>23 mmHg).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOP with comparator ORA G3 and ic100 tonometers
Description: Measurement of IOP with Ocular Response Analyzer G3 and ic100 tonometers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOP with Tono-Vera Tonometer
Description: Measurement of IOP with Tono-Vera Tonometer
Study: NCT03958474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
Study: NCT04058197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine Product
Description: Deferoxamine Intradermal Delivery Patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Patch